High blood pressure, or hypertension, affects more than a billion people worldwide and remains the leading cause of death due ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria . Approval based on phase 3 studies demonstrating Dupixent signifi ...

Neuroimmune modulation represents a promising treatment strategy that uses vagus nerve stimulation to reduce inflammation in RA.